QualityMetric Provides Translations for Global Study in Youth Living with HIV
Caregiver-completed pediatric survey was developed in 12 different languages, including new translated versions to ensure comparable measures.
Frontier Science, the Data Management Center for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, and QualityMetric, a global provider of patient-reported outcome (PRO) and clinical outcome assessment (COA) solutions, announced their collaboration on IMPAACT 2036/CRAYON: The Cabotegravir and Rilpivirine Long-Acting Injections in YOung ChildreN study. This Phase I/II study will assess the safety, tolerability, acceptability, and pharmacokinetics of these medications in children living with HIV-1. The study will enroll up to 90 children between the ages of 2 and 12 worldwide over the next three years and is expected to begin enrolling this month.
To measure physical and emotional aspects of child health, CRAYON will utilize QualityMetric's SF-10 caregiver-completed pediatric survey in 12 different languages, including new translated versions for Setswana (spoken in Botswana), Luganda (Uganda), isiXhosa, isiZulu, Sesotho, and Afrikaans (South Africa). QualityMetric's translation process provided the new language options for the SF-10 be easily understood by caregivers and will produce comparable assessments of functional health across all participating research sites, as well as support IRB submission and translation validation.
"Our team was excited to assist with cultural, linguistic validation and support the study team in obtaining valuable feedback from participants by utilizing our high-quality surveys," stated Angie Lee, Manager of Linguistics with QualityMetric. With the inclusion of cognitive interview testing with local speakers of each new language, the translations underwent an extra measure of practical testing to confirm cultural relevance, comprehension, and validity. K Rivet Amico, study team member from the University of Michigan, School of Public Health, noted that, "Being able to measure child mental and functional health confidently, with the same tool, for all participating study sites is a great advantage for global network trials like CRAYON."
Reference: Frontier Science and QualityMetric Collaborate on Worldwide Treatment Study in Youth Living with HIV. BOSTON, May 31, 2023. PRNewswire.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
